No Data
Athira Pharma To Focus On Advancement Of ATH-1105 For The Treatment Of Neurodegenerative Diseases, Includes A Reduction In Workforce Of ~70%. Athira Expects One-Time Costs Of ~$2.8M And Cost Savings Of ~$13.4M On An Annualized Basis
HC Wainwright & Co. Reiterates Buy on Akero Therapeutics, Maintains $50 Price Target
Unveiling 7 Analyst Insights On Avidity Biosciences
Cantor Fitzgerald Reiterates Overweight on Avidity Biosciences, Maintains $96 Price Target
Oxford Industries Reports Weak Results, Joins Viper Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease